Skip to main content
Journal ArticleOPEN ACCESS

Efficacy and Safety of Erythropoiesis-Stimulating Proteins in Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis

  • Ross S
  • Allen I
  • Probst C
  • et al.
The Oncologist (2007) 12(10) 1264-1273
DOI: 10.1634/theoncologist.12-10-1264
64Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

After completing this course, the reader will be able to: Provide the current best estimates of hemoglobin response with erythropoiesis-stimulating proteins in anemia of MDS.Specify prognostic factors for response that are potentially useful.Describe the gaps in the existing evidence base regarding these agents in MDS.Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com

Cite

CITATION STYLE

APA

Ross, S. D., Allen, I. E., Probst, C. A., Sercus, B., Crean, S. M., & Ranganathan, G. (2007). Efficacy and Safety of Erythropoiesis-Stimulating Proteins in Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis. The Oncologist, 12(10), 1264–1273. https://doi.org/10.1634/theoncologist.12-10-1264

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free